EP2560489A4 - Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof - Google Patents

Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof

Info

Publication number
EP2560489A4
EP2560489A4 EP20100850371 EP10850371A EP2560489A4 EP 2560489 A4 EP2560489 A4 EP 2560489A4 EP 20100850371 EP20100850371 EP 20100850371 EP 10850371 A EP10850371 A EP 10850371A EP 2560489 A4 EP2560489 A4 EP 2560489A4
Authority
EP
European Patent Office
Prior art keywords
inhibitors
enzyme
compositions
opioid prodrugs
cleavable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20100850371
Other languages
German (de)
French (fr)
Other versions
EP2560489A1 (en
Inventor
Thomas E Jenkins
Craig O Husfeld
Julie D Seroogy
Jonathan W Wray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signature Therapeutics Inc
Original Assignee
Signature Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signature Therapeutics Inc filed Critical Signature Therapeutics Inc
Publication of EP2560489A1 publication Critical patent/EP2560489A1/en
Publication of EP2560489A4 publication Critical patent/EP2560489A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EP20100850371 2010-04-21 2010-04-21 Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof Withdrawn EP2560489A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2010/031953 WO2011133149A1 (en) 2010-04-21 2010-04-21 Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof

Publications (2)

Publication Number Publication Date
EP2560489A1 EP2560489A1 (en) 2013-02-27
EP2560489A4 true EP2560489A4 (en) 2014-01-22

Family

ID=44834413

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20100850371 Withdrawn EP2560489A4 (en) 2010-04-21 2010-04-21 Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof

Country Status (9)

Country Link
EP (1) EP2560489A4 (en)
JP (1) JP2013525348A (en)
CN (1) CN102917589A (en)
AU (1) AU2010351605C1 (en)
BR (1) BR112012026768A2 (en)
CA (1) CA2795222A1 (en)
IL (1) IL222354A0 (en)
RU (1) RU2012149438A (en)
WO (1) WO2011133149A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG179026A1 (en) * 2009-09-08 2012-04-27 Signature Therapeutics Inc Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof
JP6016810B2 (en) * 2011-01-11 2016-10-26 シグネーチャー セラピューティクス, インク.Signature Therapeutics, Inc. Composition comprising an enzyme-cleavable oxycodone prodrug
US11634384B2 (en) 2014-11-25 2023-04-25 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
JP2019516773A (en) 2016-05-25 2019-06-20 コンセントリック アナルジジックス，インク． Prodrugs of phenol TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
WO2018160178A1 (en) 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
EP3684417A1 (en) * 2017-09-19 2020-07-29 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Lipophilic peptide prodrugs
WO2019058374A1 (en) 2017-09-19 2019-03-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. N-methylated cyclic peptides and their prodrugs
JP2021532183A (en) 2018-07-27 2021-11-25 コンセントリック アナルジェジクス，インク． PEGylated prodrug of phenolic TRPV1 agonist
CA3161341A1 (en) 2019-12-11 2021-06-17 Masoud Fakhr Tavazoie Methods of treating cancer
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140272A2 (en) * 2006-05-26 2007-12-06 Pharmacofore, Inc. Controlled release of phenolic opioids
WO2008101187A2 (en) * 2007-02-16 2008-08-21 Pharmacofore, Inc. Pro-drugs of peripheral phenolic opioid antagonists
WO2010045599A1 (en) * 2008-10-17 2010-04-22 Pharmacofore, Inc. Pharmaceutical compositions with attenuated release of phenolic opioids

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU781255B2 (en) * 1998-12-15 2005-05-12 Applied Biosystems, Llc Multiple enzyme assays
US7060708B2 (en) * 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
EP1928881A2 (en) * 2005-08-19 2008-06-11 Pharmacofore, Inc. Prodrugs of active agents
CA2624179A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
CN101528264B (en) * 2006-05-26 2014-02-26 特色疗法股份有限公司 Controlled release of phenolic opioids
SG179026A1 (en) * 2009-09-08 2012-04-27 Signature Therapeutics Inc Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140272A2 (en) * 2006-05-26 2007-12-06 Pharmacofore, Inc. Controlled release of phenolic opioids
WO2008101187A2 (en) * 2007-02-16 2008-08-21 Pharmacofore, Inc. Pro-drugs of peripheral phenolic opioid antagonists
WO2010045599A1 (en) * 2008-10-17 2010-04-22 Pharmacofore, Inc. Pharmaceutical compositions with attenuated release of phenolic opioids

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KATRAGADDA S ET AL: "Simultaneous modulation of transport and metabolism of acyclovir prodrugs across rabbit cornea: An approach involving enzyme inhibitors", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 320, no. 1-2, 31 August 2006 (2006-08-31), pages 104 - 113, XP027972848, ISSN: 0378-5173, [retrieved on 20060831] *
PAULETTI GIOVANNI M ET AL: "Esterase-sensitive cyclic prodrugs of peptides: Evaluation of a phenylpropionic acid promoiety in a model hexapeptide", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS, NEW YORK, NY, US, vol. 14, no. 1, 1 January 1997 (1997-01-01), pages 11 - 17, XP002496921, ISSN: 0724-8741, DOI: 10.1023/A:1012091014242 *
See also references of WO2011133149A1 *
SONG XIAOPING ET AL: "Synthesis of a novel cyclic prodrug of RGD peptidomimetic to improve its cell membrane permeation.", BIOORGANIC CHEMISTRY AUG 2002, vol. 30, no. 4, August 2002 (2002-08-01), pages 285 - 301, XP002717776, ISSN: 0045-2068 *

Also Published As

Publication number Publication date
AU2010351605B2 (en) 2015-01-29
IL222354A0 (en) 2012-12-31
WO2011133149A1 (en) 2011-10-27
EP2560489A1 (en) 2013-02-27
JP2013525348A (en) 2013-06-20
CA2795222A1 (en) 2011-10-27
RU2012149438A (en) 2014-05-27
CN102917589A (en) 2013-02-06
AU2010351605A1 (en) 2012-11-22
AU2010351605C1 (en) 2015-08-06
BR112012026768A2 (en) 2015-09-29

Similar Documents

Publication Publication Date Title
HK1246715A1 (en) Compositions and methods for targeted thermomodulation
IL253870B (en) Certain amino-pyrimidines and pharmaceutical compositions comprising them
HK1172283A1 (en) Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof
IL222354A0 (en) Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
EP2606031A4 (en) Autotaxin inhibitors and uses thereof
EP2558120A4 (en) Methods and compositions for intranasal delivery
ZA201206718B (en) Pde10 inhibitors and related compositions and methods
EP2560486A4 (en) Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof
PT2579875T (en) Compositions comprising buprenorphine
EP2629742A4 (en) Hair-mending compositions and associated methods
AP3441A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
EP2624836A4 (en) Bepotastine compositions
HK1201451A1 (en) Compositions and methods
GB201018650D0 (en) Methods and compositions
IL226554A (en) Pharmaceutical compositions comprising alisporivir
EP2536431A4 (en) Compositions and methods for inhibiting mmset
EP2643340A4 (en) Compositions and methods for functional glycomics
IL215486A0 (en) Compositions of cholinesterase inhibitors
GB201018651D0 (en) Methods and compositions
GB201010083D0 (en) Compositions and methods
GB201009767D0 (en) Compositions and methods
GB201018597D0 (en) Inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20121116

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA ME RS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SIGNATURE THERAPEUTICS, INC.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1180899

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20140103

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/44 20060101ALI20131216BHEP

Ipc: A01N 43/42 20060101AFI20131216BHEP

17Q First examination report despatched

Effective date: 20150506

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20151117

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1180899

Country of ref document: HK